<DOC>
	<DOCNO>NCT00151424</DOCNO>
	<brief_summary>Schizophrenia brain disease . The primary feature schizophrenia characterize Positive symptom ( symptom , inability think clearly , distinguish reality fantasy i.e. , hear voice ) Negative symptom ( reduction absence normal behavior emotion , i.e. , unable manage emotion , make decision relate others ) . Other symptom include reduced ability recall learn new information , difficulty problem solve , maintain productive employment . The symptom schizophrenia may due imbalance chemical brain , primarily dopamine serotonin , enable brain cell communicate . Asenapine investigational drug may help correct imbalance dopamine serotonin . This 6 week study test efficacy safety asenapine comparator agent ( olanzapine ) treatment patient schizophrenia . Patients complete trial option continue additional one year extension trial .</brief_summary>
	<brief_title>Efficacy Safety Asenapine With Placebo Olanzapine ( 41022 ) ( P05947 )</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Asenapine</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Currently suffer acute exacerbation schizophrenia . Have uncontrolled , unstable medical condition . Have psychiatric disorder schizophrenia primary diagnosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>